Tilray Brands, Inc.
NASDAQ•TLRY
CEO: Mr. Irwin David Simon
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Listing Date: 2018-07-19
Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Beverage Alcohol, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. The company offers its products under the Tilray, Aphria, Broken Coast, Symbios, Navcora, Charlotte's Web, Montauk Brewing, Shock Top, 10 Barrell, Breckenridge Brewery, SweetWater Brewing, Breckenridge Distillery, Blue Point Brewing, Broken Coast, Redecan, XMG, Manitoba Harvest, CC Pharma, Good Supply, Solei, Mollo, Chowie Wowie, Original Stash, Canaca, RIFF, Bake Sale, The Batch, HEXO, Alpine Beer Company, Green Flash, Hiball Energy, Redhook Brewery, Square Mile Cider, Widmer Brothers Brewing, Runner's High Brewing Company, Happy Flower, and Fresh Hemp Foods brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.
Contact Information
Market Cap
$731.01M
P/E (TTM)
-0.3
15.1
Dividend Yield
--
52W High
$23.20
52W Low
$3.50
52W Range
Rank59Top 87.6%
2.2
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q2 2026 Data
Revenue
$303.85M+2.98%
4-Quarter Trend
EPS
-$0.57-70.69%
4-Quarter Trend
FCF
-$25.47M-60.38%
4-Quarter Trend
2026 Q2 Earnings Highlights
Key Highlights
Net Revenue Increased 4% Six-month net revenue reached $427.0M USD, marking a 4% increase driven by Distribution and Cannabis segments.
Net Loss Significantly Reduced Six-month net loss narrowed to $42.0M USD, reflecting a 65% improvement due to lower operating expenses.
Adjusted EBITDA Stable Adjusted EBITDA for six months was $18.5M USD, showing 1% growth despite gross profit decline.
Distribution Revenue Strong Distribution segment revenue grew 17% to $159.3M USD for six months, benefiting from favorable FX impacts.
Risk Factors
Beverage Margin Pressure Beverage adjusted gross margin fell to 35% (down 7 points) due to Craft Acquisition II integration and revenue decline.
U.S. Rescheduling Uncertainty Federal cannabis rescheduling introduces significant regulatory uncertainty impacting the planned 2026 U.S. medical platform launch.
Contingent Consideration Reassessment Recognized $15.0M loss on Montauk contingent consideration as achievement likelihood dropped to 0% for the earn-out.
Wholesale Revenue Declined Wholesale cannabis revenue dropped 55% to $5.5M USD as strategic shift prioritized higher margin international sales.
Outlook
Project 420 Synergy Nearing Goal Expect completion of $33M synergy plan in Q4 FY2026; $27.2M achieved to date improving gross margins.
Focus on International Cannabis Redirecting inventory to international markets expected to generate higher margins, offsetting domestic wholesale declines.
Capital Structure Optimization Intends to opportunistically purchase or exchange equity for TLRY 27 Notes before June 2027 maturity.
Cannabis Expansion Strategy Leveraging EU-GMP facilities and compliance expertise to maintain market share in international medical markets.
Peer Comparison
Revenue (TTM)
$2.73B
$1.46B
$1.17B
Gross Margin (Latest Quarter)
100.0%
96.2%
84.8%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| VRDN | $2.43B | -7.1 | -58.4% | 5.6% |
| NEOG | $2.14B | -3.6 | -26.9% | 23.6% |
| CLDX | $2.08B | -8.0 | -41.7% | 0.4% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
4.2%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Deep Research
Next earnings:Apr 6, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data